| Literature DB >> 35050988 |
Emmanouil Mavrogeorgis1,2, Harald Mischak1, Agnieszka Latosinska1, Antonia Vlahou3, Joost P Schanstra4,5, Justyna Siwy1, Vera Jankowski2, Joachim Beige6,7, Joachim Jankowski2,8.
Abstract
Collagen is a major component of the extracellular matrix (ECM) and has an imminent role in fibrosis, in, among others, chronic kidney disease (CKD). Collagen alpha-1(I) (col1a1) is the most abundant collagen type and has previously been underlined for its contribution to the disease phenotype. Here, we examined 5000 urinary peptidomic datasets randomly selected from healthy participants or patients with CKD to identify urinary col1a1 fragments and study their abundance, position in the main protein, as well as their correlation with renal function. We identified 707 col1a1 peptides that differed in their amino acid sequence and/or post-translational modifications (hydroxyprolines). Well-correlated peptides with the same amino acid sequence, but a different number of hydroxyprolines, were combined into a final list of 503 peptides. These 503 col1a1 peptides covered 69% of the full col1a1 sequence. Sixty-three col1a1 peptides were significantly and highly positively associated (rho > +0.3) with the estimated glomerular filtration rate (eGFR), while only six peptides showed a significant and strong, negative association (rho < -0.3). A similar tendency was observed for col1a1 peptides associated with ageing, where the abundance of most col1a1 peptides decreased with increasing age. Collectively the results show a strong association between collagen peptides and loss of kidney function and suggest that fibrosis, potentially also of other organs, may be the main consequence of an attenuation of collagen degradation, and not increased synthesis.Entities:
Keywords: CE-MS; chronic kidney disease; collagen alpha-1(I) chain; fibrosis; urine
Mesh:
Substances:
Year: 2021 PMID: 35050988 PMCID: PMC8781252 DOI: 10.3390/toxins14010010
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Number of samples per disease aetiology investigated in the study.
| Disease Aetiology | Number |
|---|---|
| Controls | 1717 |
| Amyloidosis | 3 |
| Diabetes mellitus | 2756 |
| Focal segmental glomerulosclerosis | 27 |
| IgA nephropathy | 247 |
| Minimal change disease | 16 |
| Membranous glomerulopathy | 28 |
| Membranoproliferative glomerulopathy | 2 |
| Nephritis | 3 |
| Nephrosclerosis | 135 |
| Systemic lupus erythematosus | 22 |
| Steroid-Resistant Nephrotic Syndrome | 4 |
| Vasculitis | 40 |
Figure 1Study design. Datasets of 5000 participants were initially obtained from the Human Urinary Proteome Database. In this database, 707 col1a1 protein fragments that satisfied a frequency threshold of 100 participants, were detected. Of these, 359 peptides corresponded to unique amino acid sequences, while 348 peptides corresponded to 144 unique amino acid sequences, but included different numbers of PTMs. The correlation analysis of the latter (348 peptides) resulted in the identification of 119 peptides which were further combined due to their high rho values to 55 unique col1a1 fragments as well as 229 peptides that were not combined due to their low rho values, but were reduced to 89 unique col1a1 fragments. Thus, a final list of 503 unique col1a1 fragments was included in further analysis, which involved correlation with eGFR and also age. The results indicate that 435 peptides were significantly correlated with eGFR and 408 with age (p-values were corrected for multiple testing). All 503 sequences were used as an input for the alignment with the sequence of the main protein.
Figure 2Boxplots of the Spearman’s rank correlation coefficient (rho) per hydroxyproline number difference. The graph illustrates a potential association between peptides with identical amino acid sequence, but differing in the number of hydroxyproline residues they carry (differences of n = 1, 2, 3 and 4). The green- and red-colored points represent the peptides that were (green) or were not (red) combined for the further analyses, based on the 0.5 rho threshold.
Figure 3Alignment of 503 col1a1 fragments detected by CE-MS. Peptides were aligned to the col1a1 sequence from an amino acid position of 136 until 1218. The peptides correlated with eGFR (corrected for multiple testing) with rho > +0.3 are colored green, whereas the red color indicates rho < −0.3. The rest of the fragments are colored grey. The bars on the right of the sequences indicate the normalized relative total abundance of significantly (corrected for multiple testing) correlated (orange) or non-significantly correlated (purple) peptides with eGFR. On each bar, diamond, square or triangle black-colored shapes may appear in case the peptide belonged to the top ten: lowest p-values, highest total intensity or (absolute) Spearman’s rank correlation coefficient (rho), respectively. The figure is also provided online as Supplementary Figure S2 for more in-depth higher resolution studying.
Top ten strongest correlations with eGFR based on the (absolute) Spearman’s rank correlation coefficient (rho) and p-values. The association of these peptides with age is also listed. AA: amino acid. p: Hydroxyproline.
| Sequence | Start | Stop AA | rho eGFR | eGFR | rho Age | Age |
|---|---|---|---|---|---|---|
| ADGQpGAKGEpGDAGAKGDAGpPGPAGPAGPpGPIG | 819 | 854 | 0.61 | 0.00 | −0.39 | 1.14 × 10−180 |
| IGPpGPAGApGDKGESGPSGPAGPTG | 769 | 794 | 0.59 | 0.00 | −0.38 | 7.36 × 10−172 |
| LTGPIGppGPAGAPGDKGESGPSGPAGPTG | 765 | 794 | 0.57 | 0.00 | −0.36 | 1.19 × 10−153 |
| pPGADGQPGAKGEpGDAGAKGDAGppGPAGPAGPPGPIG | 816 | 854 | 0.55 | 0.00 | −0.34 | 2.69 × 10−132 |
| PpGPAGFAGPPGADGQPGAKGEpGDAGAKGDAGPPGPAGP | 807 | 846 | 0.54 | 0.00 | −0.31 | 7.21 × 10−110 |
| LDGAKGDAGPAGPKGEpGSpGENGApG | 273 | 299 | 0.50 | 0.00 | −0.38 | 5.05 × 10−169 |
| TGPIGpPGPAGAPGDKGESGpSGPAGPTG | 766 | 794 | 0.50 | 0.00 | −0.29 | 3.64 × 10−94 |
| GPpGADGQPGAKGEpGDAGAKGDAGPPGpAGPAGPPGpIG | 815 | 854 | 0.50 | 1.02 × 10−305 | −0.35 | 3.06 × 10−142 |
| GADGQpGAKGEpGDAGAKGDAGPPGPAGPAGPpGPIG | 818 | 854 | 0.48 | 1.42 × 10−291 | −0.27 | 6.08 × 10−81 |
| NGDDGEAGKPGRpGERGPpGPQG | 229 | 251 | 0.48 | 3.41 × 10−279 | −0.25 | 3.26 × 10−69 |
Top ten strongest (based on absolute Spearman’s rank correlation coefficient (rho) and p-values) correlations with age-corrected eGFR (top) or with age in eGFR-matched subjects (bottom). Each set of ten peptides is ordered based on the respective bold, B-H corrected p-value. The two peptides that are among the ten most significant in both comparisons are indicated in red. The generally lower p-value for association with age is a result of a lower number of subjects in this dataset (960 vs. 5000) and should not be interpreted as generally lower significance in comparison to kidney function. AA: amino acid. p: Hydroxyproline. m: Methionine sulfoxide.
|
|
|
|
|
|
|
|
| ADGQpGAKGEpGDAGAKGDAGpPGPAGPAGPpGPIG | 819 | 854 | 0.44 | −0.27 | 4.28 × 10−16 | |
| PpGPAGFAGPPGADGQPGAKGEpGDAGAKGDAGPPGPAGP | 807 | 846 | 0.41 | −0.15 | 1.92 × 10−05 | |
|
|
|
|
|
|
|
|
| PGPAGPPGEAGKPGEQGVPGDLGAPGPSGARG | 646 | 677 | −0.41 | −0.06 | 1.47 × 10−01 | |
| LTGPIGppGPAGAPGDKGESGPSGPAGPTG | 765 | 794 | 0.40 | −0.27 | 5.95 × 10−16 | |
|
|
|
|
|
|
|
|
| TGPIGpPGPAGAPGDKGESGpSGPAGPTG | 766 | 794 | 0.38 | −0.24 | 1.22 × 10−12 | |
| NGDDGEAGKPGRpGERGPpGPQG | 229 | 251 | 0.37 | −0.22 | 1.15 × 10−10 | |
| KEGGKGPRGETGPAGRpGEVGPpGPpGPAG | 903 | 932 | 0.37 | −0.10 | 6.96 × 10−03 | |
| GADGQpGAKGEpGDAGAKGDAGPPGPAGPAGPpGPIG | 818 | 854 | 0.37 | −0.21 | 6.90 × 10−10 | |
|
|
|
|
|
|
|
|
| DAGPAGPKGEpGSpGENGApG | 279 | 299 | 0.21 | 2.87 × 10−52 | −0.39 | |
| LDGAKGDAGPAGPKGEpGSpGENGApG | 273 | 299 | 0.31 | 9.95 × 10−111 | −0.36 | |
| pGpAGEKGSpGADGPAGAP | 928 | 946 | 0.02 | 2.58 × 10−01 | 0.36 | |
| GLPGpAGppGEAGKPGEQGVPGDLGApGP | 644 | 672 | 0.16 | 2.92 × 10−30 | −0.36 | |
| ADGQpGAKGEpGDAGAKGDAGPPGPAGP | 819 | 846 | 0.30 | 1.83 × 10−101 | −0.35 | |
| GSpGSpGPDGKTGPpGPAG | 542 | 560 | 0.21 | 4.83 × 10−48 | −0.35 | |
| EpGSpGENGAPGQmGPR | 288 | 304 | 0.09 | 3.28 × 10−11 | 0.32 | |
|
|
|
|
|
|
|
|
| EGSPGRDGSPGAK | 1021 | 1033 | 0.15 | 4.99 × 10−26 | 0.28 | |
|
|
|
|
|
|
|
|